Skip to main content

Table 3 Follow-up details of subjects who had further treatment after the phase Ib study

From: Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients

Patient Prior therapies Response to prior line Duration of response (months) No. of AZA-vorinostat cycles Subsequent therapies Time between combination to subsequent therapy (days) Response to subsequent therapies TTP post-study (days) OS post-study (days) Survival status
1 RCHOP (×6) CR 40 3 Veltuzumab with 90Y-epratuzumab 14 Significant clinical benefit 115 682 Dead
2 RCHOP (×6), VIPER (×3), BEAM, and ASCT PD NA 4 Oral PEP-C 16 Significant clinical benefit 408 556 Alive
3 CHOP + RT 10 years prior. De Angelis, RDICE (×3) CR 8 2 Oral PEP-C 18 CR 220 501 Alive
4 RCHOP (×6), RDICE, RHCVAD (Bcycle) PD NA 2 Brentuximab + PEP-C (×4) 2 PD 79 148 Dead
5 RCHOP (×6), ESHAP (×3), lenalidomide, ibrutinib PD NA 4 RDICE (×3), ASCT 11 CR 436 825 Dead
6 RCHOP (×6), RDICE (×2), ibrutinib PD NA 1 Bendamustine (×1) 1 Significant clinical benefit NA 45 Dead
7 RCHOP (×6), RICE (×2), R-Nav/Gem#1 PD NA 1 Bendamustine (×1) 4 NA NA 35 Alive
  1. Time to progression and overall survival calculated from the time the subject was taken off the study
  2. RCHOP rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisolone, VIPER bortezomib in combination with DICE chemotherapy plus rituximab, BEAM combination of carmustine, etoposide, cytarabine, and melphalan, ASCT autologous stem cell transplant, RT radiotherapy, RHCVAD rituximab-fractionated cyclophosphamide, vincristine, adriamycin, and dexamethasone, ESHAP etoposide, methylprednisolone, cytarabine and cisplatin, RCIE rituximab, ifosfamide, carboplatin, and etoposide, CR complete remission, PD progressive disease, NA not available, PEP-C prednisone, etoposide, procarbazine, and cyclophosphamide, TTP time to progression, OS overall survival